These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 7970942

  • 21. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
    Köhler M, Miyashita C.
    Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
    Mehta P, Parker RI.
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Value of coagulation function and fibrinolytic system assessment in patients with gestational diabetes mellitus].
    Liu BY, Jian YL, Zhong M, Yu YH, Wang Q, Zhang J.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):35-7. PubMed ID: 17259140
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
    Brommer EJ, Derkx FH, Schalekamp MA, Dooijewaard G, vd Klaauw MM.
    Thromb Haemost; 1988 Jun 16; 59(3):404-11. PubMed ID: 3142078
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
    Pedersen OD, Gram J, Bagger H, Keller N, Jespersen J.
    Coron Artery Dis; 1994 Jul 16; 5(7):617-23. PubMed ID: 7952424
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins.
    Bulava A, Slavík L, Fiala M, Heinc P, Skvarilova M, Lukl J, Krcová V, Indrák K.
    J Interv Card Electrophysiol; 2004 Jun 16; 10(3):271-9. PubMed ID: 15133367
    [Abstract] [Full Text] [Related]

  • 38. Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing's disease.
    Pecori Giraldi F, Ambrogio AG, Fatti LM, Rubini V, Cozzi G, Scacchi M, Federici AB, Cavagnini F.
    Br J Clin Pharmacol; 2011 Jan 16; 71(1):132-6. PubMed ID: 21143510
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome.
    van de Kar NC, Monnens LA, Karmali MA, van Hinsbergh VW.
    Blood; 1992 Dec 01; 80(11):2755-64. PubMed ID: 1333300
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.